Business Description Imclone Systems, Inc. is engaged in the research and development of novel cancer treatments. The Company focuses on growth factor inhibitors, therapeutic cancer vaccines and angiogenesis inhibitors. The Company's lead product candidate, IMC-C225, is a therapeutic monoclonal antibody that inhibits stimulation of a receptor for growth factors upon which certain solid tumors depend in order to grow. IMC-C225 has been shown in several Phase I/II trials to have an acceptable safety profile, to be well tolerated and, when administered with either radiation therapy or chemotherapy, to enhance tumor reduction. The Company is also developing inhibitors of angiogenesis, which could be used to treat various kinds of cancer and other diseases. Imclone has identified IMC-1C11 as its lead clinical candidate for angiogenesis inhibition. IMC-1C11 is an antibody that binds selectively and with high affinity to KDR, a principal Vascular Endothelial Growth Factor (VEGF) receptor, inhibiting angiogenesis.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.